Drug intelligence / Profile preview

Perfectha Subskin Lidocaine

Development stage: Unknown
Lead developer: Sinclair
Modality: Small Molecules
Administration: Subcutaneous, Implant

Overview

Perfectha Subskin Lidocaine is a sterile, viscoelastic, injectable dermal filler manufactured by Sinclair Pharma. It is composed of cross-linked hyaluronic acid (20 mg/mL) of non-animal origin, synthesized using the proprietary E-brid™ cross-linking technology, and includes 0.3% lidocaine to minimize patient discomfort during the procedure. The product is designed for deep subcutaneous or supraperiosteal injection to provide structural volume and hydration to the extracellular matrix. It is primarily indicated for the non-surgical correction of facial volume loss in the cheeks, jawline, and chin, with clinical results typically lasting between 12 and 18 months.

Brand names: Perfectha Subskin Lidocaine

Targets

NaV (Voltage-gated sodium channels)

Beyond the preview

Go deeper on Perfectha Subskin Lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Perfectha Subskin Lidocaine.

Explore the full profile